Mitochondrial diabetes mellitus (MDM) is a rare subtype of diabetes caused by mitochondrial dysfunction, often accompanied by hepatic steatosis. Coenzyme Q10 (CoQ10), a key electron carrier and antioxidant, may improve mitochondrial function and lipid metabolism. This prospective study aims to evaluate the effect of 12-week CoQ10 supplementation (300 mg/day) on liver fat content (assessed by FibroTouch CAP ) in MDM patients with m.3243A>G mutation. An exploratory case-control design will compare baseline characteristics among MDM patients, type 1 diabetes patients, and healthy controls. This study is the first to explore the link between mitochondrial defects and hepatic fat accumulation specifically in MDM, and to test CoQ10 as a potential therapy, offering new insights for both MDM and MAFLD management.

Start Date01 Sep 2026

Sponsor / Collaborator-

IRCT20260510069330N1

/ SuspendedPhase 3IIT

Studying the effect of Coenzyme Q10 tablets on the incidence of contrast- associated acute kidney injury in patients undergoing diagnostic coronary angiography

Start Date01 Sep 2026

Sponsor / Collaborator

Tehran University of Medical Sciences

CTRI/2026/06/112563

/ Not yet recruitingNot Applicable

Effect of Coenzyme Q10 Supplementation in Trigeminal Neuralgia: A Randomized Controlled Trial - NIL

Start Date15 Jul 2026

Sponsor / Collaborator-

100 Clinical Results associated with Ubidecarenone

100 Translational Medicine associated with Ubidecarenone

100 Patents (Medical) associated with Ubidecarenone

6,523

Literatures (Medical) associated with Ubidecarenone

01 Dec 2026·JOURNAL OF BIOENERGETICS AND BIOMEMBRANES

Coenzyme Q10 exerts anti-cancer effects in bladder cancer by inducing ROS-mediated apoptosis and autophagy

Article

Author: Zhao, Liping ; Wang, Yebo ; Gao, Jingyu ; Xu, Zhe ; Zhang, Aimin ; Che, Hang ; Wang, Zhao ; Luo, Zijing

Bladder cancer (BCa) is one of the most common types of cancer that impacts the urinary system, and its incidence is increasing worldwide. Coenzyme Q10 (CoQ10) is a naturally occurring fat-soluble quinone with anti-oxidant and anti-inflammatory properties, and it plays a significant role in the suppression of tumor growth. Our objective was to elucidate the potential molecular mechanisms by which CoQ10 affects the advancement of BCa. In our study, human BCa cells 5637 and T24 and normal ureteral epithelial cells SV-Huc-1 were treated with different concentrations of CoQ10. Cell viability, reactive oxygen species (ROS) levels, apoptosis rate, and autophagy levels were assessed by CCK-8 assay, ROS assay kits, flow cytometry, reverse transcription quantitative PCR (RT-qPCR), and western blot analysis. Additionally, xenograft mouse models were conducted to investigate tumor growth. Our data indicated that CoQ10 decreased the viability of 5637 and T24 cells in a concentration- and time-dependent manner, while having minimal impact on SV-Huc-1 cells. Functional experiments uncovered that CoQ10 suppressed cell proliferation, and increased ROS levels, apoptosis, and autophagy in BCa cells. The application of the ROS inhibitor N-Acetyl-L-cysteine (NAC) significantly mitigated these effects. Furthermore, CoQ10 was found to block the Keap1-Nrf2 pathway, whereas the activator of Nrf2 (tert-Butylhydroquinone, TBHQ) and the agonist of HO-1 (Hemin) partially reversed CoQ10-induced ROS accumulation, apoptosis, and autophagy. In the BCa mouse model, CoQ10 inhibited tumor growth, apoptosis, autophagy, and the Keap1-Nrf2 pathway. These findings demonstrated that CoQ10 could be a therapeutic agent for BCa by promoting ROS-mediated apoptosis and autophagy via the Keap1-Nrf2 pathway.

01 Oct 2026·FOOD AND CHEMICAL TOXICOLOGY

Conventional and nonconventional therapies for pesticide-induced cardiotoxicity: A systematic review

Review

Author: Meireles, Mario Henrique Veiga ; Joviano-Santos, Julliane V ; Teles, Alessandra Silva ; de Almeida, Douglas Lamounier ; da Costa, Sarah Júnia Gomes ; Silva, Verônica Cecília ; Santos-Miranda, Artur

Pesticides, as pervasive environmental pollutants, have been associated with cardiotoxic effects. However, evidence regarding cardioprotective strategies remains fragmented, particularly concerning the integration of conventional therapies and nonconventional approaches involving natural products. This systematic review (PROSPERO:CRD420251143191) aimed to synthesize experimental evidence on cardioprotection against pesticides, with emphasis on natural product-based interventions. The review was conducted according to PRISMA, with searches performed in Medline/PubMed, EMBASE, and BVS. Eligible studies included in vitro and in vivo models of pesticide exposure that reported cardiovascular outcomes and therapeutic interventions. A total of 85 studies were included, predominantly involving in vivo models. While only a few studies evaluated conventional antidotes, such as atropine and pralidoxime, most investigated natural and bioactive compounds, including antioxidant vitamins, polyphenols, flavonoids, carotenoids, and microbiota-modulating agents. Frequently studied compounds included vitamin E, vitamin C, lycopene, coenzyme Q10, resveratrol, and curcumin. Overall, these interventions demonstrated protective effects through attenuation of lipid peroxidation, restoration of endogenous antioxidant defenses, and modulation of inflammatory and apoptotic pathways. Studies also reported improvements in hemodynamic and electrocardiographic parameters. Collectively, these findings provide promising preclinical evidence that novel interventions may mitigate pesticide-induced cardiotoxicity, although they should be interpreted with caution due to the predominantly preclinical nature of the studies.

01 Sep 2026·Atherosclerosis plus

Effects of evolocumab on plasma coenzyme Q10 in patients with heterozygous familial hypercholesterolemia

Article

Author: Takamura, Masayuki ; Takeji, Yasuaki ; Tada, Hayato

Background and aims:

Muscle symptoms are common with statin therapy, and reduced plasma coenzyme Q10 (CoQ10) has been proposed as a potential mechanism. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are widely used in patients with statin intolerance or severe hypercholesterolemia, including familial hypercholesterolemia (FH), but their effects on plasma CoQ10 remain unclear.

Methods:

We evaluated serum lipid profiles and plasma CoQ10 baseline and 4 weeks after adding evolocumab in patients with heterozygous FH receiving rosuvastatin 10-20 mg/day and ezetimibe 10 mg/day (N = 10; mean age, 52 years; 6 men). Plasma CoQ10 concentrations were determined by high-performance liquid chromatography.

Results:

Evolocumab markedly reduced LDL cholesterol and lipoprotein(a) [Lp(a)] (121 mg/dL to 64 mg/dL, -50.0%, p < 0.001; 51.8 nmol/L to 39.1 nmol/L, -23.6%, p = 0.002), whereas median CoQ10 levels were unchanged (1028.5 nmol/L to 1002.5 nmol/L, -0.2%, p = 0.33). Changes in CoQ10 did not correlate with reductions in LDL cholesterol or Lp(a).

Conclusions:

These findings indicate that evolocumab lowers atherogenic lipoproteins without reducing plasma CoQ10, suggesting a potential advantage for patients susceptible to statin-associated muscle symptoms.

News (Medical) associated with Ubidecarenone

07 Sep 2026

·www.prnewswire.com

U.S. District Court Invalidates Kaneka's Ubiquinol Patent, Clearing the Way for Cocrystal Tech's CrysQnol™ in the U.S. Market

Judge Overturns Kaneka's '080 Patent for Lack of Utility and Enablement, Removing Legal Uncertainty for Customers and Partners JIAXING, China, Sept. 7, 2026 /PRNewswire/ -- Cocrystal Technology (Jiaxing) Co., Ltd. ("Cocrystal Tech") today announced that the U.S. District Court for the Eastern District of New York has ruled in the company's favor in its long-running patent dispute with Kaneka Corporation, holding that the two patent claims asserted against Cocrystal Tech are invalid. In a Memorandum and Order issued September 2, 2026 in Kaneka Corp. vs. Cocrystal Technology (Jiaxing) Co., Ltd. et al., Case No. 1:23-cv-07483 (E.D.N.Y.), the Court found that Kaneka failed to meet the utility and enablement requirements of U.S. patent law, entered judgment in Cocrystal Tech's favor, and closed the case. As a result, Cocrystal Tech is entitled to continue to manufacture, market, and sell its reduced coenzyme Q10 (ubiquinol) ingredient, marketed under the CrysQnol™ trademark, in the United States without restriction under the invalidated patent. Kaneka filed suit against Cocrystal Tech in October 2023 in the Eastern District of New York, alleging that Crystal QH® - Cocrystal Tech's flagship ubiquinol ingredient, now marketed as CrysQnol™ - infringed U.S. Patent No. 7,829,080 (the "'080 Patent"). The asserted claims cover compositions of reduced coenzyme Q10 containing any amount of reduced coenzyme Q11, a naturally occurring minor component found in CoQ10 materials. Although Cocrystal Tech stipulated that its product fell within the literal language of the asserted claims, it maintained throughout the litigation that the claims were invalid. Following nearly two years of fact and expert discovery, the Court agreed, finding on summary judgment that Kaneka's asserted invention was based on an untested hypothesis rather than a patentable invention. The Court further noted that even Kaneka's own inventors and expert witnesses could not explain, and had never studied, how or why coenzyme Q11 would have any stabilizing effect. The ruling brings welcome finality to a dispute that has spanned nearly three years and removes a significant source of uncertainty for the U.S. nutraceutical industry. With the asserted patent claims invalidated, brand partners, formulators, CMOs and distributors can evaluate CrysQnol™ on its own technical and commercial merits - including stability, bioavailability, formulation flexibility, supply security, and cost efficiency. The decision also underscores years of investment in Cocrystal Tech's proprietary cocrystal stabilization technology, reinforcing the company's position as an innovator in the global ubiquinol ingredient market. "Our focus has never been on following an established path, but on solving difficult scientific problems through our own research and technology," said Dr. Xuefeng Mei, Founder of Cocrystal Tech. "We are pleased that the Court has recognized the importance of the issues at stake in this case. For us, the ruling marks not an endpoint, but an opportunity to bring our technology to more customers and continue innovating in the U.S. market". Introducing CrysQnol ™ : The New Name for Cocrystal's Ubiquinol In conjunction with this legal milestone, Cocrystal Tech - owner of the Crystal QH® trademark - has initiated the transition to its new CrysQnol™ brand, formalizing the rebrand across its global trademark matrix. Customers and partners can expect full continuity of formulation and specifications through the transition, with the CrysQnol™ brand now serving as the unified identity for Cocrystal's ubiquinol ingredient. The favorable ruling comes as Cocrystal Tech continues to expand its portfolio of premium, science-backed nutritional ingredients. Built on the company's proprietary Cocrysta™ technology platform, Cocrystal Tech's ingredient lineup - including CrysQnol™, CurCutine™, Precitein™, and UroRenu™ - is designed to improve the stability, bioavailability, and performance of some of the industry's most in-demand nutraceutical compounds. Cocrystal Tech remains committed to protecting and growing its intellectual property portfolio and to investing in the research that differentiates its ingredients in an increasingly competitive global market. About Cocrystal Tech Cocrystal Tech is the world's first company to apply pharmaceutical-grade cocrystal technology to human nutrition. We are committed to creating higher-value nutrition solutions that deliver more with less. We believe true innovation goes beyond advancing science. For us, it means making nutrition solutions more sustainable, more accessible, and more impactful for people everywhere. Our ingredients and formulations are now trusted across North America, Europe, and Asia-Pacific by leading brands and partners worldwide. For more information, visit . Media Contact: Christina Huang, Marketing Director Cocrystal Technology (Jiaxing) Co., Ltd. [email protected] SOURCE Cocrystal Technology (Jiaxing) Co., Ltd. 21% more press release views with Request a Demo

Patent Infringement

03 Sep 2026

·www.prnewswire.com

KANEKA UBIQUINOL™ WINS NUTRAINGREDIENTS ASIA INGREDIENT OF THE YEAR: HEALTHSPAN AWARD 2026

Award Shines Spotlight on Ubiquinol's Role in Mitochondrial Health and Mitoceutical Innovation in the Global Healthspan MovementSeventh International Accolade Affirms Kaneka Ubiquinol™ Leadership in Evidence-Based Mitochondrial Health, Supporting Healthspan from Preconception to Healthy Ageing[i]The Lancet Public Health, August 2026: Global lifespan–healthspan gap widens to 10.7 years, underscoring the importance of supporting general health and wellbeing throughout life, especially in ageing individuals[ii] BANGKOK, Sept. 3, 2026 /PRNewswire/ -- Kaneka Corporation, the sole global manufacturer of Ubiquinol, is thrilled to announce that Kaneka Ubiquinol™ has been awarded Ingredient of the Year: Healthspan Award at the NutraIngredients-Asia Awards 2026. The highly coveted award represents Kaneka Ubiquinol's third consecutive recognition at the NutraIngredients-Asia Awards, following Healthy Ageing Ingredient of the Year as the Winner in 2024 and the Innovation in Women's Health Award as a Finalist in 2025. Continue Reading Kaneka Ubiquinol™ was named Ingredient of the Year – Healthspan at the NutraIngredients-Asia Awards 2026, spotlighting mitochondrial health and the emerging “mitoceuticals” category. Kaneka Ubiquinol™ wins NutraIngredients-Asia Healthspan Ingredient of the Year. From left: Tingmin Koe, Editor, NutraIngredients-Asia; Kazuki Takita, Assistant Manager, Marketing & Sales (APAC), Kaneka Ubiquinol™; Tsuyoshi Takakuwa, Head of Marketing & Sales APAC, Kaneka Corporation; and Gary Scattergood, Managing Director Asia, William Reed and Publisher, NutraIngredients-Asia. The latest accolade recognises Kaneka Ubiquinol™ at a pivotal time in healthcare, as attention increasingly shifts beyond lifespan – the number of years we live – towards healthspan: maintaining health and wellbeing throughout life. At the heart of this conversation is mitochondrial health. Mitochondria, commonly referred to as the 'powerhouses of the cell', are fundamental to cellular energy production, found in almost every cell in the body[iii]. The endogenous antioxidant Ubiquinol, supports the production of energy in the mitochondria and helps reduce cellular free radical damage[iv]. This growing "mitoceutical" category - nutraceuticals purpose-formulated to support mitochondrial function - is central to advancing healthspan science. Evidence shows that each heart cell contains approximately 5000+ mitochondria,[v] with every cell in the body powered by mitochondria, supporting energy production from preconception to healthy ageing, placing mitochondrial health at the centre of Kaneka's decades-long research into Ubiquinol[vi]. "To receive our seventh international accolade and third consecutive recognition from NutraIngredients-Asia is an extraordinary honour," said Tsuyoshi Takakuwa, Head of Marketing and Sales (APAC), Supplemental Nutrition Business Division, Kaneka Corporation. "We sincerely thank the judges, our customers, research partners, healthcare professionals and our team who continue to advance understanding of Ubiquinol and mitochondrial health worldwide. We also congratulate our fellow finalists and winners." "Our vision extends across the lifespan, supporting healthspan from preconception to general health and wellbeing with ageing. As an innovation partner to brands worldwide, we are committed to combining 50+ years of Ubiquinol research with scientific education, ingredient expertise and collaboration to help advance health solutions globally," said Kazuki Takita, Assistant Manager, Marketing and Sales (APAC), Kaneka Ubiquinol™. Gary Scattergood, Managing Director Asia, William Reed, Publisher of Nutraingredients Asia remarked, "the judges were hugely impressed with the wealth of scientific evidence behind the ingredient, as well as the significant evidence of commercial success across the region, with an impressive line-up of advocates across medical and healthcare practitioners." ABOUT KANEKA UBIQUINOL™ Kaneka Corporation is the sole global manufacturer of clinically researched bioidentical Ubiquinol, produced via an award-winning Japanese natural fermentation process. Backed by 110+ scientific studies, 80+ patents and 50+ years of research, antioxidant-active Ubiquinol supports mitochondrial health, cardiovascular health, cognition, women's health, reproductive health, energy and wellbeing. Listed in 50+ countries in 1,000+ practitioner and OTC nutraceutical brands since 2006. Kaneka Ubiquinol's adherence to the highest manufacturing standards guarantees a stable ingredient, free from impurities, meeting rigorous quality and sustainability requirements — setting the benchmark for production quality via its unique, globally patented yeast fermentation process. Kaneka Ubiquinol™ carries multiple certifications, including HALAL, GRAS, HACCP, NDI, KOSHER, GMP, ISO 14001, ISO 22000, Non-GMO, Non-Animal Origin, and OSHMS. Kaneka Ubiquinol™ is the proud winner of multiple awards: NutraIngredients-Asia Ingredient of the Year: Healthspan Award 2026 Vitafoods Europe Innovation Award 2026 — Most Innovative Consumer-Ready Nutraceutical Finished Product, in partnership with Eqology Pure Arctic Oil Heart & Energy Tmall Global Marketing Innovation Award 2025 Finalist, NutraIngredients-Asia Innovation in Women's Health Award 2025 Natural Health Products New Zealand Forbes Packaging Marketing Award 2025 CMA Raw Material Supplier of the Year Award 2024 NutraIngredients-Asia Healthy Ageing Ingredient of the Year Award 2024 EMAIL: [email protected] WEBSITE: SOURCE Kaneka Ubiquinol™ 21% more press release views with Request a Demo

12 Aug 2026

·www.globenewswire.com

Olympia Pharmaceuticals Advances Longevity Offerings With Advanced Injectable CoQ10 Formulation

Formulated in an advanced MCT oil base, the new 20 mg/mL formulation offers healthcare providers an effective, patient-friendly option for mitochondrial and cardiovascular healthORLANDO, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Olympia Pharmaceuticals, a premier FDA-registered 503B outsourcing facility and 503A pharmacy, today announced the launch of its new Coenzyme Q-10 (CoQ-10) injectable formulation. Expanding Olympia’s suite of longevity and preventive health treatments, this addition offers healthcare providers a specialized compounded therapy that supports cellular energy, strengthens antioxidant defenses, and supports overall vitality. Delivered at a concentration of 20 mg/mL in a 30 mL multidose vial for intramuscular (IM) or subcutaneous (SQ) use, Olympia’s CoQ-10 injection is engineered in a Medium Chain Triglycerides (MCT) oil containing 2% Ubidecarenone (Coenzyme Q-10). This formulation allows for optimal absorption while delivering a smoother injection experience with reduced site discomfort compared to traditional heavy oil bases. CoQ-10 plays a critical role in cellular function, specifically within the mitochondria, where cellular energy (ATP) is generated. Because organs with the highest energy demands, such as the heart and muscles, rely heavily on CoQ-10, natural age-related declines can impact daily physical stamina and cardiovascular efficiency. Targeted parenteral administration helps support these key biological pathways, promoting heart health, daily energy output, and cellular resilience against oxidative stress. "At Olympia, our work is driven by a desire to help people feel their best and live healthier, more vibrant lives," said Joshua Fritzler, President of Olympia Pharmaceuticals. "CoQ-10 is a cornerstone of daily energy and long-term health, but the delivery method matters just as much as the ingredient. By formulating this with a lighter MCT oil, we’re making it easier for clinicians to give their patients a smooth, comfortable experience that yields real results." Injectable administration bypasses the digestive tract entirely, offering a direct route to systemic circulation for patients who experience absorption barriers with oral supplements. "The clinical advantage of an injectable CoQ-10 lies in its efficiency and reliable uptake," said Dr. Christopher Lorich, PharmD, Pharmacist at Olympia Pharmaceuticals. "Bypassing GI barriers ensures a dependable, direct route of administration that practitioners can seamlessly integrate into comprehensive wellness and anti-aging protocols." The new CoQ-10 injection is now available to order across 49 states for clinical office use and patient-specific prescriptions. "As demand accelerates for targeted longevity therapies, providers are looking for trusted pharmacy partners who can deliver pure, reliable formulations," said Hayden Goldman, Director of Commercial Sales at Olympia Pharmaceuticals. "Adding CoQ-10 to our nationwide catalog helps our clinical partners stay at the forefront of preventive care." For more information about Olympia and Wesley Pharmaceuticals, visit olympiapharmacy.com or call 407-673-2222. About Olympia PharmaceuticalsOlympia Pharmaceuticals is a state-of-the-art, FDA-registered 503B pharmaceutical outsourcing facility and 503A pharmacy supporting both patient-specific and office-use needs across the U.S. Co-founded by Stan and Naomi Loomis, the team is made up of pharmacy technicians, pharmacists, quality personnel, and engineers, creating an educated and experienced staff knowledgeable in all facets of pharmacy production. As an FDA-registered outsourcing facility, Olympia offers compounded medications to 49 states for both office use and patient prescriptions. Olympia specializes in weight loss, dermatology, IV nutritional therapy, erectile dysfunction, and more. About Wesley PharmaceuticalsWesley Pharmaceuticals, a sister brand of Olympia Pharmaceuticals, was co-founded by Stan and Naomi Loomis in 2024 in honor of Wesley Loomis, their son and a beloved team member. Based in Orlando, Florida, the company plans to deliver high-quality compounded medications across therapeutic areas, including weight management, hormone replacement therapy, and wellness. Rooted in compassion and patient-first care, Wesley is dedicated to supporting pharmacies and providers with innovative solutions that improve lives. Media ContactDaniele SpringUproar by Moburst for Olympia and Wesley PharmaceuticalsDaniele.Spring@Moburst.com

100 Deals associated with Ubidecarenone

External Link

KEGG	Wiki	ATC	Drug Bank
D01065	Ubidecarenone	C01EB09	DB09270

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Heart Failure	Japan	Eisai Co., Ltd.	27 Jul 1976

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pancreatic Cancer	Phase 2	United States	Berg LLC	30 Jan 2022
Squamous Cell Carcinoma	Phase 2	-	BPGbio Inc	01 Mar 2008
Superficial basal cell carcinoma	Phase 2	United States	BPGbio Inc	01 Mar 2008
Multiple System Atrophy	Phase 2	Japan	Nobelpharma Co., Ltd.	-
Glioblastoma	Phase 1	United States	Berg LLC	30 Jan 2022
Brain Cancer	Phase 1	United States	BPGbio Inc	01 Oct 2013
Brain metastases	Phase 1	United States	BPGbio Inc	01 Oct 2013
Colorectal Cancer	Phase 1	United States	BPGbio Inc	01 Oct 2013
Alzheimer Disease	Preclinical	Canada	University of Windsor	19 Jun 2026
Parkinson Disease	Preclinical	Canada	University of Windsor	19 Jun 2026

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06570811 (Pubmed \| BMC Pharmacol Toxicol)	Phase 3	Breast Cancer	60	Paclitaxel + CoQ10	oslevmhoen(afzjexnaxh) = mqkfchdetj iwxuwkwqht (ycvplgveoi ) View more	Positive	04 Jul 2026
				Paclitaxel	oslevmhoen(afzjexnaxh) = igxbejzzgn iwxuwkwqht (ycvplgveoi ) View more
AACR2026	Not Applicable	-	47	Reduced coenzyme Q10 (rCoQ10)	vnjadugmfq(juromeodtk) = While the overall incidence and severity distribution of diarrhea did not significantly differ, a trend toward reduced occurrence of Grade 2 diarrhea was observed in the rCoQ10 group. bxlxulzbpm (vxciqzpaor ) View more	Negative	21 Apr 2026
				Placebo
NCT05871086 (Pubmed \| Immunopharmacol Immunotoxicol)	Phase 3	Juvenile Idiopathic Arthritis	58	CoQ10 (100 mg/day)	mnyxjjvalc(dpldcrsnta) = byyeletnrb vyvgugpyob (rophardzwl ) View more	Positive	15 Apr 2026
				Placebo	mnyxjjvalc(dpldcrsnta) = seilhgobsd vyvgugpyob (rophardzwl ) View more
NCT06405204 (Pubmed \| Drug Des Devel Ther)	Phase 3	-	100	Coenzyme Q10 + folic acid	mobyfrfnrm(qplcuxtkdy): P-Value = 0.001 View more	Positive	01 Mar 2026
				folic acid
NCT06452134 (Pubmed \| Pain Manag)	Phase 4	-	70	Coenzyme Q10 supplementation	dlugelxcew(sibfwgbpab) = xaalnrgfea ptbhhjztgp (gvjcmbvjpf ) View more	Positive	02 Sep 2025
				coenzyme Q10 (Placebo)	ruxsnkyxvl(rwgpfkccws) = pwyqrfqlsq gpffuxrncx (hbjdbuhjso ) View more
NCT02865460 (CTgov)	Phase 3	Fatigue Syndrome, Chronic \| Persian Gulf Syndrome \| Coenzyme Q10 Deficiency	100	Ubiquinol (Ubiquinol)	mawmtlqxmn(gwfolrqyln) = udeqkrjhjs ngqweraglt (gxmofgykzw, 11.1) View more	-	15 Feb 2023
				Placebo (Placebo)	mawmtlqxmn(gwfolrqyln) = yungckrruo ngqweraglt (gxmofgykzw, 10.1) View more
EUCTR2020-005961-16-DK \| NCT04960215 (Pubmed)	Phase 2	Post Acute COVID 19 Syndrome	121	Coenzyme Q10 500 mg/day	ygmuryywer(pnisqlfqdj): mean difference = 0.01 (95% CI, -0.02 to 0.04), P-Value = 0.45 View more	Negative	02 Nov 2022
				coenzyme Q10 (Placebo)
NCT03133793 (Pubmed)	Phase 2	Heart failure with normal ejection fraction	216	Placebo ubiquinol capsules and d-ribose powder	wyghewzzkn(gqizdnfeqc) = fysqfdkqmo twmtyoutgk (rlyslvozpg ) View more	Positive	01 Aug 2022
				Ubiquinol capsules (600 mg/d) and placebo d-ribose powder	wyghewzzkn(gqizdnfeqc) = xufnplcaig twmtyoutgk (rlyslvozpg ) View more
NCT03133793 (CTgov)	Phase 2	Heart Failure, Diastolic	216	Placebo powder (Placebo Only)	jmxsamjujb(vqiisqkujl) = kanzprmxbj jyineulsjr (gvzwcgayil, 24.04) View more	-	03 Mar 2022
				Placebo powder+CoQ10 (CoQ10 Only)	jmxsamjujb(vqiisqkujl) = xrajtcbrik jyineulsjr (gvzwcgayil, 18.61) View more
NCT02934555 (CTgov)	Phase 2	Post-Cardiac Arrest Syndrome \| Heart Arrest	48	Ensure+Ubiquinol	jtcrfkcrnp(dtbjtlfmrn) = xcxixofiyq swyswiislc (fqsbgshfzy, lgfswnlraf - ajzyriiiul) View more	-	15 Feb 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis